Rentschler
| Rentschler Biotechnologie GmbH
|
|
|---|---|
 |
|
| legal form | GmbH |
| founding | 1927 |
| Seat | Laupheim , Germany |
| management | Frank Mathias, Thomas Siklosi |
| Number of employees | 790 |
| sales | EUR 137.8 million |
| Branch | Service company for biopharmaceuticals, pharmaceuticals |
| Website | www.rentschler.de |
| As of March 31, 2017 | |
The Dr. Rentschler Holding GmbH & Co. KG comprises a group of companies with over 790 employees. The largest contribution is made by Rentschler Biopharma SE as an international service company for the production of biopharmaceuticals in mammalian cells with headquarters in Laupheim in the Biberach district in Upper Swabia .
Area of activity of Rentschler Biopharma SE
The company offers its customers in the pharmaceutical and biotechnology industries services for the production of biopharmaceuticals. These include the service areas of cell line and process development, GMP production, formulation, filling, analysis, quality control, approval and quality assurance.
For production, GMP systems are available for cultivation on a scale of 250 to 3000 liters; a further expansion is planned.
history
The company's history goes back to 1872, when the pharmacist Gottlob Müller set up a pharmacy in Laupheim , which he sold to his son-in-law, pharmacist Erwin Rentschler senior in 1909. handed over, and which continues to this day as the “ 7-Schwaben-Apotheke ”. After 140 years in the possession of the Rentschler family, the pharmacy was sold in 2012.
On New Year's Eve 1923/24, the pharmacist Erwin Rentschler jun., Son of Erwin Rentschler senior, created the basis for the group of companies that exists today. During the night shift he had the idea for a new pain reliever formulation that was marketed under the name “Melabon”. Since the pharmacy became too small to meet the demand for Melabon, the Dr. Rentschler & Co. OHG with Erwin Rentschler jun. as managing director. Two years later, his brother, Helmut Rentschler, pharmacist and chemist, also became a managing partner and together with him managed the young company, which was initially based on a single preparation. Over time, other non-prescription drugs were added and established a tradition that goes back almost 80 years. The first product diversification took place in 1947 with the establishment of the Bacteriological Institute Warthausen, which was dedicated to the development and production of veterinary vaccines.
After the death of Erwin Rentschler jun. In 1959 his son, Friedrich Erwin Rentschler , took over the management. He gradually expanded the portfolio of over-the-counter preparations with new prescription products, mainly in the cardiovascular area. In 1974, he created the Biotechnology division and began developing interferons , which eventually resulted in Rentschler receiving the world's first approval in 1983 for a natural beta-interferon compound sold under the brand name Fiblaferon . Work with recombinant cell technologies began in 1979, with the result that a GMP plant for the production of recombinant interferon-gamma could be put into operation as early as 1986. In 1993, all biotechnological activities were merged into Rentschler Biotechnologie GmbH , which since 1997 has concentrated all business activities on services for the development of biopharmaceutical products.
One year after Friedrich E. Rentschler handed over the management to his son Nikolaus F. Rentschler in 1999, the expansion of biotechnology and the focus of all business activities on this area began. In 2003 the group of companies was restructured within Rentschler Holding GmbH & Co. KG. Rentschler Biotechnologie GmbH provides the largest operational share. The expansion of biotechnology, which began in 2000, was continued, so that in 2010 nine plants will be available for GMP production of biopharmaceuticals for clinical development projects and for market supply.
family
The Rentschler Group is 100% family-owned.
The family is involved in volunteer and civic projects in their hometown of Laupheim , such as B. in the Bioregion Ulm and in the Biberach University . Furthermore, she is committed to clubs, u. a. in the Friends of the Museum for the History of Christians and Jews in Laupheim.
Friedrich E. Rentschler, former chairman of the supervisory board, was awarded the Federal Cross of Merit and the Merit Medal of the State of Baden-Württemberg . He was also chairman of the Laupheim community foundation. In 2009 he opened rooms in the Ulm city shelf for his private collection of international contemporary art, the “Sammlung FER Collection”, which is accessible after registration. Friedrich E. Rentschler died on July 19, 2018.
Nikolaus F. Rentschler followed in January 2016 as Chairman of the Supervisory Board.
Web links
Individual evidence
- ↑ Consolidated financial statements as of March 31, 2018 in the electronic Federal Gazette
- ↑ Annual financial statements as of March 31, 2017 in the electronic Federal Gazette
- ↑ Rolf Dieterich: "Rentschler is a real pioneer in biotechnology" - from the series: "Companies with Tradition" in: Schwäbische Zeitung, October 13, 2012. Here online , accessed on October 14, 2012.
- ↑ Rolf Dieterich: Obituary for Friedrich E. Rentschler: Between biotechnology and fine arts. Retrieved June 20, 2019 .